biOasis Technologies Inc. (V:BTI)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Mar 21, 2024 07:47 am ET

Canadian Investment Regulatory Organization Trading Halt - BTI

VANCOUVER, BC, March 21, 2024 /CNW/ - The following issues have been halted by CIRO

Jun 20, 2023 05:25 pm ET

Bioasis Provides Corporate Update and Announces Suspension of Operations

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary...

Mar 23, 2023 05:05 pm ET

Bioasis Provides Update on Business Operations

Feb 03, 2023 05:39 pm ET

Bioasis Announces AGM Results and Provides Update on Financial Position

Jan 23, 2023 09:22 am ET

Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc

Jan 23, 2023 08:48 am ET

IIROC Trading Resumption - BTI

VANCOUVER, BC, Jan. 23, 2023 /CNW/ - Trading resumes in:

Jan 23, 2023 07:50 am ET

IIROC Trading Halt - BTI

VANCOUVER, BC, Jan. 23, 2023 /CNW/ - The following issues have been halted by IIROC:

Jan 19, 2023 05:05 pm ET

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022

Jan 11, 2023 05:05 pm ET

Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholders

Dec 19, 2022 07:47 am ET

Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc

Dec 14, 2022 08:00 pm ET

Bioasis Technologies Inc. Announces Shareholder Webinar

BIOASIS TECHNOLOGIES INC. (TSXV:BTI) (OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary...

Dec 13, 2022 12:29 pm ET

Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc

Dec 13, 2022 11:36 am ET

IIROC Trading Resumption - BTI

VANCOUVER, BC, Dec. 13, 2022 /CNW/ - Trading resumes in:

Dec 13, 2022 08:39 am ET

IIROC Trading Halt - BTI

VANCOUVER, BC, Dec. 13, 2022 /CNW/ - The following issues have been halted by IIROC:

Oct 28, 2022 05:18 pm ET

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary...

Aug 08, 2022 05:47 pm ET

Bioasis Technologies Inc. Announces Stock Option Grants

Jul 29, 2022 05:23 pm ET

Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A

BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced...

Jun 16, 2022 07:50 am ET

Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”) a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced...

Jun 14, 2022 06:51 pm ET

Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the...

May 10, 2022 05:30 pm ET

Bioasis and Neuramedy Enter into Research Collaboration and License Agreement

BIOASIS TECHNOLOGIES INC.. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced...

Apr 11, 2022 04:05 pm ET

Bioasis Enters Into Research Collaboration With Janssen

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”), a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”),...

Mar 09, 2022 04:30 pm ET

Bioasis to Attend and Present at Upcoming Industry Conference

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the...

Feb 17, 2022 04:05 pm ET

Bioasis Announces $200,000 Non-Brokered Private Placement

Jan 20, 2022 05:01 pm ET

Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021

Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the...

Dec 16, 2021 04:31 pm ET

Bioasis Announces Annual General Meeting Results

Dec 09, 2021 04:30 pm ET

Bioasis to Attend and Present at Upcoming Industry Conferences

Nov 29, 2021 04:30 pm ET

Bioasis Announces Annual General Meeting Details

Oct 28, 2021 05:50 pm ET

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain...

Sep 30, 2021 04:05 pm ET

Bioasis to Attend Upcoming Industry Conferences

Aug 18, 2021 04:05 pm ET

Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor

Aug 09, 2021 05:00 pm ET

Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfatase

Jul 29, 2021 04:28 pm ET

Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A

Jul 20, 2021 04:05 pm ET

Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager

Jul 07, 2021 04:05 pm ET

Bioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple Sclerosis

Jul 01, 2021 04:05 pm ET

Bioasis Announces the Appointment of Dave Jenkins as Chief Financial Officer

Jun 30, 2021 04:05 pm ET

Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) (“Bioasis”) and Oxyrane UK Ltd. (“Oxyrane”) are pleased to announce the initiation of a research collaboration. Bioasis is a pre-clinical, research-stage biopharmaceutical company developing a...

Jun 29, 2021 04:05 pm ET

Bioasis Technologies Announces Closing of Initial C$3,000,000 Funding by Lind Partners

Bioasis Technologies Inc. (“Bioasis” or the “Company”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain...

Jun 25, 2021 05:33 pm ET

Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain...

Jun 22, 2021 08:10 pm ET

Bioasis Technologies enters into Convertible Security Funding Agreement for Institutional Investment of up to C$10 million

Jun 03, 2021 04:05 pm ET

Bioasis Announces Publication Validating its xB³ ™ Platform Technology for CNS Therapeutics

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain...

Mar 31, 2021 04:05 pm ET

Bioasis Technologies Inc. and Aposense Enter into a Research Collaboration

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain...

Mar 29, 2021 04:05 pm ET

Bioasis Announces Publication of CNS Delivery of siRNA via xB³ ™ Platform Technology

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain...

Mar 24, 2021 05:15 pm ET

Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing

BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF;), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the...

Mar 22, 2021 06:30 pm ET

Bioasis Technologies Inc. Announces Warrant Extension and Repricing

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”) a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain...

Mar 08, 2021 04:05 pm ET

Bioasis to Attend and Present at Upcoming Investor and Industry Conferences

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain...

Feb 10, 2021 07:02 pm ET

Bioasis Announces Shares for Debt Transaction

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the...

Jan 29, 2021 04:05 pm ET

Bioasis Announces $200,000 Non-Brokered Private Placement

Jan 27, 2021 04:05 pm ET

Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020

Jan 22, 2021 09:19 am ET

Bioasis Announces Stock Option Grant

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the...

Jan 04, 2021 04:05 pm ET

Bioasis to Present at Upcoming Industry Conferences

BIOASIS TECHNOLOGIES INC. – Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of...

Dec 10, 2020 04:05 pm ET

Bioasis Announces Annual General Meeting Results

BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics...

Nov 10, 2020 04:05 pm ET

Bioasis Announces Annual General Meeting Details

Nov 03, 2020 04:05 pm ET

Bioasis Announces Sale of Royalty Interest in Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance to XOMA Corporation

Nov 03, 2020 07:30 am ET

XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance

XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies Inc. (TSXV:BTI.V; OTCQB:BIOAF), associated with the advancement of the enzymes being investigated as...

Oct 29, 2020 04:58 pm ET

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2020

Oct 22, 2020 04:05 pm ET

Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain...

Oct 20, 2020 04:05 pm ET

Bioasis Announces Issuance of US Patent Relating to xB³™ Platform Technology for The Delivery of Therapeutic Agents Across the Blood-Brain Barrier

Jul 27, 2020 05:03 pm ET

Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending May 31, 2020

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical n

Jul 09, 2020 05:24 pm ET

Bioasis and Chiesi Group to Host Webcast on July 16, 2020

On June 29, 2020 Bioasis and Chiesi Global Rare Diseases announced that they entered into a worldwide, exclusive licensing agreement for the xB3 BBB platform technology in treatment of rare diseases with a focus on four undisclosed lysosomal storage disorders (“LSDs”).

Jul 07, 2020 09:00 am ET

Bioasis Announces Stock Option Grants

Jun 29, 2020 06:15 pm ET

Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in

Jun 29, 2020 04:34 pm ET

IIROC Trading Resumption - BTI

VANCOUVER, BC, June 29, 2020 /CNW/ - Trading resumes in:

Jun 29, 2020 04:00 pm ET

Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

BIOASIS TECHNOLOGIES INC. (“Bioasis”) (TSXV:BTI.V; OTCQB:BIOAF),a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including rare genetic diseases, brain cancers, neurodegenerative diseases and pain, and Chiesi Global Rare Diseases, a business unit of Chiesi Gr

Jun 29, 2020 08:45 am ET

IIROC Trading Halt - BTI

VANCOUVER, BC, June 29, 2020 /CNW/ - The following issues have been halted by IIROC:

Jun 24, 2020 03:33 pm ET

Bioasis Announces Conversion of Debenture Interest Into Equity

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in

Jun 17, 2020 04:20 pm ET

Bioasis Announces Analyst Coverage Initiated by Edison Group

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSXV:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in a

Apr 06, 2020 11:08 am ET

Bioasis Completes Redemption of 15% Unsecured Debentures With Unanimous Debentureholder Approval

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”) a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in a

Apr 01, 2020 09:15 am ET

Bioasis Announces Shares for Debt Transaction

Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disord

Mar 06, 2020 09:00 am ET

Bioasis Announces Proposed Redemption of 15% Unsecured Debentures

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system

Mar 04, 2020 05:12 pm ET

Bioasis Technologies Announces the Appointment of Dr. May Orfali to the Position of Consultant Chief Medical Officer

Feb 24, 2020 07:35 am ET

Growth Company Investor Presentations Now Available for On-Demand Viewing

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

Feb 14, 2020 07:35 am ET

Live Investor Conference & Webinar: Growth Company CEOs Present February 20th

Company executives will share vision and answer audience questions at VirtualInvestorConferences.com

Feb 06, 2020 04:10 pm ET

Bioasis to Present at the 22nd Annual BIO CEO Investor Conference and the OTC Markets 2020 Virtual Investor Conference

Bioasis Technologies Inc. (OTCQB:BIOAF)(TSX.V:BTI), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,

Jan 29, 2020 06:35 pm ET

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2019

Jan 29, 2020 04:10 pm ET

Bioasis Technologies Inc. Announces Warrant Extension and Repricing

Bioasis Technologies Inc. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has applied for approval from the TSX Venture Exchange to extend the expiry date of 4,588,978 common share purc

Jan 06, 2020 05:25 pm ET

Bioasis Announces Shares for Debt Transaction

About Bioasis

Jan 06, 2020 04:30 pm ET

Bioasis to Present at Upcoming Industry Conferences

Dec 23, 2019 04:30 pm ET

Bioasis Completes Bridge Financing Transaction

Dec 16, 2019 12:23 pm ET

Bioasis Announces Bridge Financing

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it intends to complete a bridge financing transaction (the “Bridge Financing”) for gross proceeds of approximately

Dec 05, 2019 04:05 pm ET

Bioasis Announces Annual General Meeting Results

Dec 04, 2019 04:05 pm ET

Bioasis Appoints Consultant Chief Medical Officer and Nominates Medical Oncology Advisory Board

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the creation of the Medical Oncology Advisory Board and the appointments of Dr. John DeGroot M.D., Dr. Hope Rugo M.D. and Dr. Javier Cortés M.D. P

Nov 27, 2019 04:05 pm ET

Bioasis to Host Annual General Meeting Webcast on December 5, 2019

Nov 25, 2019 04:05 pm ET

Bioasis Announces Director Resignation

Nov 14, 2019 04:05 pm ET

Bioasis Announces Issuance of Japanese Patent Relating to xB3™ Platform Technology for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier

Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announces that the Japanese Patent Office (“JPO”) issued Japanese Patent No. 6603227 for the Company’s platform technology.

Nov 08, 2019 04:05 pm ET

Bioasis Completes Financing Transactions

Oct 28, 2019 10:16 am ET

Bioasis Announces Bridge Financing

Oct 25, 2019 05:44 pm ET

CORRECTING and REPLACING Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2019

First paragraph, first sentence of release should read: Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central

Oct 25, 2019 04:05 pm ET

Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending August 31, 2019

Sep 23, 2019 04:05 pm ET

Bioasis Announces Proposed Private Placement

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including

Sep 10, 2019 04:05 pm ET

Bioasis Announces Allowance of Patent Application in Japan Relating to xB3 Platform Technology for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier

Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of

Aug 29, 2019 04:05 pm ET

Bioasis Announces Stock Option Grants

Aug 21, 2019 04:05 pm ET

Bioasis Announces Registration and Grant Notice of Patent Application in China Relating to xB3 Platform Technology for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier

Aug 15, 2019 04:05 pm ET

Bioasis Strengthens Senior Management Team with Appointment of Caroline Dircks, Ph.D. as Chief Operating Officer

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet me

Jul 26, 2019 04:45 pm ET

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2019

Jul 17, 2019 04:05 pm ET

Bioasis Announces Stock Option Grants

Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cance

Jun 25, 2019 04:05 pm ET

Bioasis Announces FDA Response to Pre-IND Submission

Jun 24, 2019 04:05 pm ET

Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic Indications

May 30, 2019 04:05 pm ET

Bioasis Appoints Mario Saltarelli as Non-Executive Director of the Board of Directors

May 21, 2019 04:05 pm ET

Bioasis Announces Closing of Previously Disclosed Private Placement

BIOASIS TECHNOLOGIES INC. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment

May 06, 2019 07:06 pm ET

Bioasis Announces Private Placement

BIOASIS TECHNOLOGIES INC. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment

Mar 25, 2019 08:00 am ET

Bioasis Technologies Inc. Announces Warrant Extension

Mar 11, 2019 05:01 pm ET

Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, i

Jan 29, 2019 04:30 pm ET

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2018

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and ne

Jan 09, 2019 08:30 am ET

Bioasis Announces the Appointment of Christine Antalik as Chief Financial Officer

Jan 07, 2019 08:30 am ET

Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology

Dec 13, 2018 04:30 pm ET

Bioasis to Present at Investor & Industry Conferences in January 2019

Bioasis Technologies Inc. (TSX.V:BTI)(OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in ar

Dec 10, 2018 08:30 am ET

Bioasis Appoints Dr. Deborah A. Rathjen as Executive Chair of the Board of Directors

Nov 26, 2018 04:45 pm ET

Bioasis Announces Voting Results for 2018 Annual and Special Meeting

Nov 20, 2018 11:27 pm ET

Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001™

Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high

Oct 30, 2018 04:30 pm ET

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2018

Oct 29, 2018 08:00 am ET

Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena

Oct 04, 2018 04:30 pm ET

Bioasis Announces Investor Relations Service Agreement with Stern IR

Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancer

Aug 31, 2018 08:46 am ET

Bioasis Announces Stock Option Grants

Aug 16, 2018 08:00 am ET

Aeromics, Inc. Appoints Pharmaceutical and Biotech Veterans Mark Day, Ph.D. and Thomas Zindrick, J.D. to Its Board of Directors

Aeromics, Inc. (“Aeromics” or “the Company”), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema, or brain swelling, for people affected by disabling and life-threatening severe ischemic stroke, announced today the appointments of Mark Day, Ph.D. and Thomas Zindrick, J.D.

Aug 13, 2018 04:26 pm ET

Bioasis Announces Closing of Previously Disclosed Private Placement

BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of central nervous system (CNS) disorders,

Jul 30, 2018 06:04 pm ET

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2018

Jul 27, 2018 08:30 am ET

Bioasis Welcomes John E. Curran & David M. Wurzer to the Company’s Board of Directors

Jul 25, 2018 08:10 am ET

Bioasis Announces Positive Results from a Microdialysis Study Showing Lead Investigational Candidate xB3 ™-001 Increased Brain Activity

Jul 16, 2018 08:00 am ET

Bioasis Announces Non-Brokered Private Placement

BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of CNS disorders, today announced that it int

Jul 11, 2018 08:00 am ET

Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic

BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, and

Jun 26, 2018 08:22 pm ET

Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

Jun 12, 2018 08:30 am ET

Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor

BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing xB3 TM, a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, including brain cancers and neurodegenerative diseases, today announ

May 30, 2018 08:30 am ET

Bioasis Announces Publication of Independent Validation of the Company’s xB3 ™ Platform Technology

May 24, 2018 08:30 am ET

Bioasis Announces Closing of Second Tranche of Previously Disclosed Private Placement

BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 ™proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of CNS disorders in areas of high unmet medi

May 21, 2018 08:30 am ET

Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of xB3-001, the Company’s Lead Investigational Candidate to Treat Brain Cancer

BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) and WUXI BIOLOGICS (2269.HK) today announced an initial s

May 17, 2018 04:45 pm ET

Bioasis Announces Closing of First Tranche of Previously Disclosed Private Placement

May 14, 2018 08:30 am ET

Bioasis Announces Private Placement and Intention to Pursue NASDAQ Listing

BIOASIS TECHNOLOGIES INC. (TSX.V:BTI)(OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of CNS disorders in areas of high unmet medic

Mar 26, 2018 08:00 am ET

Bioasis Announces Key Strategic Appointment to its Senior Leadership Team with Addition of Caroline Hill, Ph.D., Leading Research & Development Operations

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company with a proprietary blood-brain barrier platform delivery technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced a key strategic appointment to its senior leader

Mar 21, 2018 08:00 am ET

Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board of Directors

BIOASIS TECHNOLOGIES, INC. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company with a proprietary blood-brain barrier platform technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced that Dr. Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD,

Feb 06, 2018 01:28 pm ET

Bioasis to Present at the 20th Annual BIO CEO & Investor Conference

Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that it will present at the 20th Annual BIO CEO & Investor Conference, to be held February 12-13, 2018 at the New York Marriott Marquis.

Jan 30, 2018 08:00 am ET

Bioasis Announces Filing of Quarterly Financial Statements and MD&A

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier (BBB) and into the central nervous system for the treatment of neurological diseases and disorders, today announced that it has filed its unaudited quarterly financial

Dec 04, 2017 12:22 pm ET

IIROC Trade Resumption - biOasis Technologies Inc.

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2017) - Trading resumes in:

Dec 04, 2017 11:52 am ET

IIROC Trade Halt - biOasis Technologies Inc.

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2017) - The following issues have been halted by IIROC:

Dec 04, 2017 08:00 am ET

Bioasis Implements Transition Plan for Its Board of Directors

Oct 10, 2017 08:00 am ET

Bioasis Establishes U.S. Presence with Office in Connecticut

Aug 28, 2017 08:00 am ET

biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders

BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF)(TSX VENTURE: BTI) is pleased to announce its slate of nominees to the board of directors (the "Board") for election at the annual general meeting of shareholders (the "Meeting") on Thurs., Sept. 21, 2017. The...

Aug 21, 2017 08:00 am ET

biOasis Appoints Doug Williams, MBA, Executive Vice President, Chief Business Officer

BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) welcomes Doug Williams, MBA, as executive vice president, chief business officer, effective immediately. Williams will report to Dr. Mark Day, president and chief executive officer of...

Jun 25, 2017 02:22 pm ET

biOasis Appoints Catherine London, Executive Vice President, Head of Corporate Communications and Investor Relations

BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) welcomes Catherine London as executive vice president, head of corporate communications and investor relations, effective immediately. London will report to Dr. Mark Day, president and...

Jun 15, 2017 12:24 am ET

biOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities

biOasis Technologies Inc. (OTCQB: BIOAF) (TSX VENTURE: BTI) announced today it has engaged FreeMind Group to assist the Company pursue non-dilutive funding opportunities globally.The biOasis Transcend technology has been demonstrated to transport...

Jun 13, 2017 10:04 pm ET

biOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders

BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) Dr. Mark Day, chief executive officer, has issued a message to shareholders detailing plans for the advancement of the Transcend Platform and the company's in-house programs.To the...

Jun 08, 2017 11:16 pm ET

biOasis to Present at The Global Chinese Financial Forum - Shanghai Conference 2017

BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) announced today that Dr. Mark Day, the chief executive officer of biOasis, will present at the Global Chinese Financial Forum (GCFF) - Shanghai Conference 2017, in Shanghai, China, on June...

Jun 04, 2017 09:00 pm ET

biOasis to Present at the 16th International Postgraduate Course on Lysosomal Storage Disorders

BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) announced today that Dr. Mark Day, chief executive officer, will present at the 16th International Postgraduate Course on Lysosomal Storage Disorders, in Nierstein (Mainz), Germany on June...

Apr 24, 2017 05:07 pm ET

biOasis Appoints Mark Day, Ph.D., as Chief Executive Officer and Director

THIS NEWS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) (the "Company") has appointed Mark Day, Ph.D., as President and Chief Executive Officer of the Company, effective...

Apr 11, 2017 08:12 pm ET

biOasis Closes Oversubscribed Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESBIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) (the "Company") is pleased to announce that further to its press releases dated March 20,...

Mar 31, 2017 06:06 pm ET

biOasis Announces Oversubscription of Financing

Jan 22, 2017 09:30 pm ET

biOasis Provides AGM Update -- Expanding The biOasis Deal Flow Pipeline

BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier (BBB), has provided a corporate update in advance of its Annual and...

Nov 06, 2016 10:00 pm ET

biOasis Attends BIO Europe and the Lockman BT2111 Paper is Honored by being Featured on the Cover of Pharmaceutical Research's December Journal

BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced its team is attending BIO...

Oct 23, 2016 07:55 pm ET

biOasis Engages Rising Tide Equity to Increase Global Awareness

Sep 20, 2016 08:00 pm ET

biOasis Enters Into a License Agreement With Vaccinex Inc.

BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) ("biOasis"), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, today announced it has entered into a...

Aug 29, 2016 05:47 pm ET

biOasis Announces Publication of Scientific Paper -- Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer T

Jul 10, 2016 08:53 pm ET

biOasis Announces the Issuance of an Additional US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier

biOasis Technologies Inc. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the issuance of a US patent...

May 17, 2016 06:07 pm ET

biOasis Technologies Inc. to Present at BIO International Conference in San Francisco on June 7, 2016

Apr 21, 2016 06:28 pm ET

biOasis Technologies Enters Into a License Agreement With Astellas Research Institute of America LLC

biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company") announces that it has entered into a License Agreement to collaborate with Astellas Research Institute of America LLC ("Astellas"). The terms of the agreement, for...

Mar 17, 2016 11:36 pm ET

biOasis to Present at the Brains for Brain 10th Annual Workshop and Open Conference in Madrid, Spain

biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company") on Saturday, March 19, 2016 at 11:45am, will present the data from the biOasis sponsored Brains for Brain ("B4B") lysosomal storage disease ("LSD") knockout mouse study...

Feb 29, 2016 09:00 pm ET

biOasis Announces Shares for Services Settlement

biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company") wishes to announce its intention to issue 125,000 shares for services to a consultant of the Company that provides certain consulting services related to business...

Feb 11, 2016 06:09 pm ET

biOasis Technologies Inc. to Present at the 1st Annual Neuroscience BioPartnering and Investment Forum in New York on February 23, 2016

BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced today that it will be presenting at...

Ad blocking detected

biOasis Technologies Inc. (V:BTI)

Business Focus: Biotechnology & Medical Research (NEC)